Listed cancer diagnostic company Pacific Edge’s share price has jumped after the reversal of a decision that would have seen its reimbursement dropped for Medicare patients using its Cxbladder tests in the US.
The Dunedin-based company has lifted a trading halt placed this morning.
It said that
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
